MDxHealth, the maker of prostate cancer diagnostics, just acquired Dutch liquid biopsy company NovioGendix for $8.8 million. With the new urine-based test, slated for release next year under the name SelectMDx, it aims to reduce unnecessary biopsies for prostate cancer.
Molecular diagnostics company MDxHealth and partner NovioGendix have been awarded a $1.1 million grant that will be applied toward research and development of a new bladder cancer diagnostic. Belgium-based MDxHealth (BRU:MDXH), which has its U.S. headquarters in Durham, North Carolina, develops companion diagnostics for cancer treatments. The grant to MDxHealth and Dutch molecular diagnostics firm […]
Discover what tools are essential for efficient, safe surgical extractions in today’s health care landscape, from elevators to forceps and beyond.